Additional mutations of TP53, RB1, PALB2, MAP3K1, NTRK3, and KRAS suggest a unique molecular profile that may contribute to the development of neuroendocrine carcinoma in patients with FAP. The gene discussed is KRAS; the disease is neuroendocrine carcinoma.